Current Evidence on Gene-Based and Epigenetic Therapeutic, Diagnostic, and Prognostic Strategies in Epithelial-Derived Carcinomas: A Scoping Review
8 affiliations
- 1Department of Cell and Developmental Biology, , New Brunswick, NJ 08901-8554, USA;
- 2Department of Biotechnology, , Ras Al Khaimah P.O. Box 10021, United Arab Emirates;
- 3Adjunct Faculty, Department of Clinical Sciences, College of Dentistry, , Ajman P.O. Box 346, United Arab Emirates;
- 4Department of Basic Medical and Dental Sciences, College of Dentistry, , Ajman P.O. Box 346, United Arab Emirates
- 5College of Dentistry, , Abu Dhabi P.O. Box 112612, United Arab Emirates;
- 6Department of Clinical Sciences, College of Dentistry, , Ajman P.O. Box 346, United Arab Emirates;
- 7RAK College of Medical Sciences (RAKCOMS), , Ras Al Khaimah P.O. Box 11172, United Arab Emirates
- 8Department of Basic Medical and Dental Sciences, , Ajman P.O. Box 346, United Arab Emirates
Abstract
Background: Epithelial-derived carcinomas exhibit genomic instability due to genetic mutation and epigenetic dysregulation. Mechanisms such as DNA methylation, histone modifications, and noncoding RNA regulation may lead to tumor progression, immune evasion, and treatment resistance. Presently, gene-based and epigenetic therapies, including CRISPR systems, RNA interference, and chromatin-modifying agents, are reported to be effective in targeted cancer treatment. Objectives: This scoping review aims to map the evidence on gene-based technologies in epithelial-derived carcinomas, including therapeutic, diagnostic, prognostic, screening, and disease-modeling applications, and to identify molecular targets, translational outcomes, and gaps in the current evidence base. The review will characterize the molecular targets, gene-based approaches, cancer types, translational applications, and reported outcomes to identify evidence gaps, translational challenges, and priorities for future research. Methods: The scoping review was conducted as per PRISMA-ScR by conducting a literature search in databases such as PubMed, Embase, and Google Scholar, covering studies published between 2016 and 2026. In the inclusion criteria, all studies and reviews related to investigating gene-based, RNA-mediated, and epigenetic therapies in epithelial cancers were included. Thirty-six studies met the eligibility criteria. Results: Amongst the studies reviewed, the most common epithelial cancers reported were hepatocellular carcinoma, ovarian carcinoma, lung carcinoma, and pancreatic ductal adenocarcinoma. Among the epithelial-derived carcinomas identified in this review, HCC was the most frequently represented cancer; epigenetic alterations and therapies used were RNA-based therapies, CRISPR diagnostics, and epigenetic drugs. Ovarian and breast cancers targeting BRCA pathways and chromatin remodeling produced clinical translation outcomes. Lung and colorectal cancers showed moderate epigenetic involvement, often managed through combined therapeutic strategies. Pancreatic cancer therapies were limited by challenges in drug delivery despite identifiable molecular targets. Gene therapies such as CRISPR-based gene editing, RNAi/siRNA therapies, miRNA/lncRNA targeting, and HDAC inhibition were commonly reported. Conclusions: The present study indicates that the majority of epithelial-derived carcinomas can benefit from gene-based and epigenetic therapies. Though the majority of carcinomas, such as hepatocellular, have good clinical outcomes, pancreatic cancer has limited clinical translation.
Related
- Epigenetic plasticity in cancer drug resistance: mechanistic insights and strategies for therapeutic intervention
- The Role of Neutrophil Extracellular Traps (NETosis) in Systemic Lupus Erythematosus: Molecular Mechanisms, Pathogenic Roles, Diagnostic Biomarkers, and Emerging Therapeutic Strategies
- Drug-Induced Vitamin B12 Deficiency: Current Evidence, Diagnostic Challenges, and Therapeutic Strategies
- Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies
- Environmental chemical mixtures reprogram mammary epithelial development to epigenetic states associated with breast cancer.
BibTeX
@article{thomas2026current,
title = {{Current Evidence on Gene-Based and Epigenetic Therapeutic, Diagnostic, and Prognostic Strategies in Epithelial-Derived Carcinomas: A Scoping Review}},
author = {Joshua George Thomas and Mohammed Ayyub and Lovely M. Annamma and Prathibha Prasad and Sabrin Ali Azim and Sudhir Varma and Biji Thomas George and Al Moutassem Billah Khair},
journal = {Biomedicines},
year = {2026},
month = oct,
doi = {10.3390/biomedicines14102234},
url = {https://europepmc.org/article/PMC/PMC13701598},
note = {CC BY},
}
RIS
TY - JOUR
TI - Current Evidence on Gene-Based and Epigenetic Therapeutic, Diagnostic, and Prognostic Strategies in Epithelial-Derived Carcinomas: A Scoping Review
AU - Joshua George Thomas
AU - Mohammed Ayyub
AU - Lovely M. Annamma
AU - Prathibha Prasad
AU - Sabrin Ali Azim
AU - Sudhir Varma
AU - Biji Thomas George
AU - Al Moutassem Billah Khair
PY - 2026
DA - 2026/10/01
JO - Biomedicines
DO - 10.3390/biomedicines14102234
UR - https://europepmc.org/article/PMC/PMC13701598
AB - Background: Epithelial-derived carcinomas exhibit genomic instability due to genetic mutation and epigenetic dysregulation. Mechanisms such as DNA methylation, histone modifications, and noncoding RNA regulation may lead to tumor progression, immune evasion, and treatment resistance. Presently, gene-based and epigenetic therapies, including CRISPR systems, RNA interference, and chromatin-modifying agents, are reported to be effective in targeted cancer treatment. Objectives: This scoping review aims to map the evidence on gene-based technologies in epithelial-derived carcinomas, including therapeutic, diagnostic, prognostic, screening, and disease-modeling applications, and to identify molecular targets, translational outcomes, and gaps in the current evidence base. The review will characterize the molecular targets, gene-based approaches, cancer types, translational applications, and reported outcomes to identify evidence gaps, translational challenges, and priorities for future research. Methods: The scoping review was conducted as per PRISMA-ScR by conducting a literature search in databases such as PubMed, Embase, and Google Scholar, covering studies published between 2016 and 2026. In the inclusion criteria, all studies and reviews related to investigating gene-based, RNA-mediated, and epigenetic therapies in epithelial cancers were included. Thirty-six studies met the eligibility criteria. Results: Amongst the studies reviewed, the most common epithelial cancers reported were hepatocellular carcinoma, ovarian carcinoma, lung carcinoma, and pancreatic ductal adenocarcinoma. Among the epithelial-derived carcinomas identified in this review, HCC was the most frequently represented cancer; epigenetic alterations and therapies used were RNA-based therapies, CRISPR diagnostics, and epigenetic drugs. Ovarian and breast cancers targeting BRCA pathways and chromatin remodeling produced clinical translation outcomes. Lung and colorectal cancers showed moderate epigenetic involvement, often managed through combined therapeutic strategies. Pancreatic cancer therapies were limited by challenges in drug delivery despite identifiable molecular targets. Gene therapies such as CRISPR-based gene editing, RNAi/siRNA therapies, miRNA/lncRNA targeting, and HDAC inhibition were commonly reported. Conclusions: The present study indicates that the majority of epithelial-derived carcinomas can benefit from gene-based and epigenetic therapies. Though the majority of carcinomas, such as hepatocellular, have good clinical outcomes, pancreatic cancer has limited clinical translation.
SN - 2227-9059
ER -